These studies have demonstrated a clinically significant difference between cerliponase alfa treatment and historical controls; treatment with cerliponase alfa was shown to result in a slower rate of decline of motor and language function in CLN2 disease patients [9]. The gene discussed is TPP1; the disease is glycogen storage disease VI.